Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

May 31, 2029

Conditions
Diabetic NephropathiesKidney Failure, ChronicDiabetes Mellitus Type 1Heart Failure
Interventions
DRUG

Sotagliflozin

Oral sotagliflozin (200 mg per day)

DRUG

Placebo

Inactive tablets identical to sotagliflozin tablets

Trial Locations (18)

10461

RECRUITING

Albert Einstein College of Medicine / Montefiore Medical Center, The Bronx

13210

RECRUITING

SUNY Upstate Medical University, Syracuse

44195

RECRUITING

Cleveland Clinic Foundation, Cleveland

60611

RECRUITING

Northwestern University Feinberg School of Medicine, Chicago

63110

RECRUITING

Washington University, St Louis

75390

RECRUITING

University of Texas Southwestern, Dallas

80045

RECRUITING

Barbara Davis Center / University of Colorado Denver, Aurora

94305

RECRUITING

Stanford University Medical Center, Stanford

97239

RECRUITING

Oregon Health and Science University, Portland

98105

RECRUITING

University of Washington, Seattle

99204

RECRUITING

Providence Sacred Heart Medical Center, Spokane

02215

RECRUITING

Joslin Diabetes Center, Boston

T2T 5C7

RECRUITING

Unversity of Calgary, Calgary

T6G 2E1

RECRUITING

Alberta Diabetes Institute, Edmonton

V6Z 1Y6

RECRUITING

St. Paul's Hospital, Vancouver

M4G 3E8

RECRUITING

LMC Diabetes and Endocrinology, Toronto

M5G 2N2

RECRUITING

Toronto General Hospital, Toronto

H2W 1R7

RECRUITING

Institut de Recherches Cliniques de Montréal, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

The Kidney Foundation of Canada

OTHER

collaborator

The Cleveland Clinic

OTHER

collaborator

University of Michigan

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

Northwestern University

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

State University of New York - Upstate Medical University

OTHER

collaborator

Providence Medical Research Center

OTHER

collaborator

Stanford University

OTHER

collaborator

Montefiore Medical Center

OTHER

collaborator

University of Toronto

OTHER

collaborator

University Health Network, Toronto

OTHER

collaborator

University of Calgary

OTHER

collaborator

University of Alberta

OTHER

collaborator

University of British Columbia

OTHER

collaborator

Institut de Recherches Cliniques de Montreal

OTHER

collaborator

LMC Diabetes & Endocrinology Ltd.

OTHER

collaborator

Joslin Diabetes Center

OTHER

collaborator

Lexicon Pharmaceuticals

INDUSTRY

collaborator

DexCom, Inc.

INDUSTRY

collaborator

University of Washington

OTHER

collaborator

Breakthrough T1D

OTHER

lead

Alessandro Doria

OTHER